Cochlear (COH) Aktienübersicht
Cochlear Limited bietet weltweit implantierbare Hörlösungen für Kinder und Erwachsene an. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 2/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 3/6 |
COH Community Fair Values
Create NarrativeSee what 72 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
AU$70
FV
73.7% überbewertet intrinsischer Abschlag0.14%
Revenue growth p.a.
195
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
6users have followed this narrative
Cochlear Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | AU$121.62 |
| 52-Wochen-Hoch | AU$319.56 |
| 52-Wochen-Tief | AU$88.74 |
| Beta | 0.26 |
| 1 Monat Veränderung | 17.22% |
| 3 Monate Veränderung | -29.42% |
| 1 Jahr Veränderung | -59.92% |
| 3 Jahre Veränderung | -47.20% |
| 5 Jahre Veränderung | -49.17% |
| Veränderung seit IPO | 4,022.71% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jul 02
COH: Hospital Bottlenecks And Weaker Referrals Will Pressure Earnings Expectations
The analyst price target for Cochlear has been revised from A$210 to A$95, reflecting updated expectations for revenue growth, profit margins, the discount rate and future P/E as outlined in recent Street research from multiple analysts. Analyst Commentary Recent Street research on Cochlear highlights a more cautious tone despite mixed rating actions, with several bearish analysts questioning how well the current share price lines up with the revised A$95 target and the company’s execution risks.Analyseartikel • Jun 19
Cochlear (ASX:COH) Shares Could Be 44% Below Fair Value After 2026 Guidance Cut
Cochlear (ASX:COH) is back in focus after the company issued a 2026 guidance downgrade, prompting a reset in expectations for both the stock and the broader premium ASX healthcare segment. See our latest analysis for Cochlear. The 2026 guidance downgrade comes after a sharp rebound in Cochlear’s share price over the past month, with a 30 day share price return of 24.66%. However, that short term strength contrasts with a much weaker backdrop, including a 90 day share price decline of 28.23%...
Narrativ-Update • Jun 18
COH: Margin Resilience And Core Franchise Strength Will Support Future Upside
The analyst price target for Cochlear has been adjusted slightly lower to A$124.40. Analysts attribute this change to modest tweaks in the discount rate, revenue growth, profit margin and future P/E assumptions following recent mixed research updates from major brokers.Narrativ-Update • Jun 03
COH: Margin Resilience And Temporary Volume Weaknesses Will Support Future Upside
The analyst price target for Cochlear has eased slightly from about A$126.08 to A$124.60, as analysts factor in more moderate revenue growth expectations alongside marginally stronger profit margins and a slightly lower assumed future P/E, following mixed recent research views. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside if Cochlear can deliver on revenue expectations while maintaining the marginally stronger profit margins now being reflected in models.Recent updates
Narrativ-Update • Jul 02
COH: Hospital Bottlenecks And Weaker Referrals Will Pressure Earnings Expectations
The analyst price target for Cochlear has been revised from A$210 to A$95, reflecting updated expectations for revenue growth, profit margins, the discount rate and future P/E as outlined in recent Street research from multiple analysts. Analyst Commentary Recent Street research on Cochlear highlights a more cautious tone despite mixed rating actions, with several bearish analysts questioning how well the current share price lines up with the revised A$95 target and the company’s execution risks.Analyseartikel • Jun 19
Cochlear (ASX:COH) Shares Could Be 44% Below Fair Value After 2026 Guidance Cut
Cochlear (ASX:COH) is back in focus after the company issued a 2026 guidance downgrade, prompting a reset in expectations for both the stock and the broader premium ASX healthcare segment. See our latest analysis for Cochlear. The 2026 guidance downgrade comes after a sharp rebound in Cochlear’s share price over the past month, with a 30 day share price return of 24.66%. However, that short term strength contrasts with a much weaker backdrop, including a 90 day share price decline of 28.23%...Narrativ-Update • Jun 18
COH: Margin Resilience And Core Franchise Strength Will Support Future Upside
The analyst price target for Cochlear has been adjusted slightly lower to A$124.40. Analysts attribute this change to modest tweaks in the discount rate, revenue growth, profit margin and future P/E assumptions following recent mixed research updates from major brokers.Narrativ-Update • Jun 03
COH: Margin Resilience And Temporary Volume Weaknesses Will Support Future Upside
The analyst price target for Cochlear has eased slightly from about A$126.08 to A$124.60, as analysts factor in more moderate revenue growth expectations alongside marginally stronger profit margins and a slightly lower assumed future P/E, following mixed recent research views. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside if Cochlear can deliver on revenue expectations while maintaining the marginally stronger profit margins now being reflected in models.Narrativ-Update • May 09
COH: Steadier Growth Assumptions Will Support Future Upside If Execution Holds
The updated analyst price target for Cochlear has shifted from A$239.95 to A$126.08 as analysts incorporate more moderate assumptions for revenue growth, profit margins and future P/E. This reflects mixed recent research views from Citi and Morgan Stanley.
Neues Narrativ • May 09
Cochlear’s Crossroads: Temporary Setback or Structural Shift?
Cochlear Limited is an interesting company. It is a medical technology business with a specific focus on implantable hearing solutions.Narrativ-Update • Apr 21
COH: VA Access Expansion Will Support Future Upside Despite Slight Model Adjustments
The Analyst Price Target for Cochlear has been adjusted slightly lower to A$239.95 from A$244.58, as analysts now factor in modestly softer revenue growth, profit margin and future P/E assumptions, along with a slightly higher discount rate. Valuation Changes Fair Value: adjusted slightly lower from A$244.58 to A$239.95.Narrativ-Update • Apr 04
COH: VA Access Expansion And Upgraded Coverage Will Underpin Future Upside
Analysts have slightly adjusted their price target for Cochlear to A$244.58 from A$245.91. This reflects updated assumptions around discount rates and valuation multiples, while core growth and profitability expectations remain broadly unchanged.Narrativ-Update • Mar 21
COH: VA Access Expansion Will Support Future Upside Potential
Analysts have adjusted their price target on Cochlear slightly lower to A$245.91 from A$250.59, reflecting modest tweaks to assumptions around the discount rate, revenue growth, profit margins and future P/E following recent research updates. Analyst Commentary Bullish Takeaways Bullish analysts see the revised A$245.91 target as still supportive of upside potential relative to recent trading levels, suggesting the core earnings story remains intact despite the small adjustment.Narrativ-Update • Mar 06
COH: Steady Assumptions And New Access Channels Will Support Future Upside Potential
Analysts have reaffirmed their A$250.59 price target for Cochlear, citing recent research that supports steady assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent research behind the reaffirmed A$250.59 price target highlights a mix of supportive factors and watchpoints that matter for Cochlear's valuation and execution risk.Neues Narrativ • Mar 01
Cloud And R&D Investment Will Pressure Margins While Long Term Hearing Demand Supports Stability
Catalysts About Cochlear Cochlear develops and manufactures hearing implant systems for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?Narrativ-Update • Feb 20
COH: Reset Expectations And Product Adoption Will Support Future Upside Potential
Analysts have trimmed their Cochlear price target from A$301.76 to A$250.59 as they factor in slightly lower revenue growth assumptions, a marginally higher discount rate, modestly softer profit margin expectations and a reduced future P/E multiple, as highlighted in recent Street research, including the latest upgrade at RBC Capital. Analyst Commentary Recent Street commentary around Cochlear focuses on how current expectations stack up against its A$250.59 target price and what needs to go right, or wrong, for that valuation to hold.Analyseartikel • Feb 16
Cochlear (ASX:COH) Has Affirmed Its Dividend Of A$2.15
Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of April. This means...Analyseartikel • Feb 15
Some Confidence Is Lacking In Cochlear Limited (ASX:COH) As Shares Slide 26%
Cochlear Limited ( ASX:COH ) shareholders that were waiting for something to happen have been dealt a blow with a 26...
Neues Narrativ • Feb 13
Hearing Health Tailwinds And Cloud Capabilities Will Support Multi Year Earnings Expansion
Catalysts About Cochlear Cochlear develops and manufactures implantable hearing solutions for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?Analyseartikel • Feb 06
Here's Why We Think Cochlear (ASX:COH) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Narrativ-Update • Feb 05
COH: Execution Upside And Premium P/E Will Underpin Future Upside Potential
Analysts have trimmed their price target on Cochlear to about A$302 from roughly A$305, reflecting a slightly higher discount rate, modestly lower revenue growth assumptions, and a small uplift in expected profit margins and future P/E multiples. Analyst Commentary Recent research adjustments on Cochlear point to a generally constructive stance, with the trimmed price target tied to updated assumptions rather than a material change in the long term story.Analyseartikel • Jan 11
Investors Shouldn't Overlook Cochlear's (ASX:COH) Impressive Returns On Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analyseartikel • Nov 18
Risks To Shareholder Returns Are Elevated At These Prices For Cochlear Limited (ASX:COH)
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 21x, you may consider...Analyseartikel • Oct 14
Does Cochlear (ASX:COH) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyseartikel • Sep 28
We Think Cochlear (ASX:COH) Might Have The DNA Of A Multi-Bagger
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Narrativ-Update • Sep 19
Aging Population Will Spur Cochlear Implant Adoption Worldwide
Cochlear’s modestly lower consensus price target predominantly reflects a slight reduction in forecast revenue growth, resulting in a revised fair value estimate of A$305.38. What's in the News Cochlear extended its share buyback plan duration to August 28, 2026.Analyseartikel • Aug 26
Cochlear (ASX:COH) Is Due To Pay A Dividend Of A$2.15
Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of October. This...Narrativ-Update • Aug 19
New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects
Cochlear’s consensus price target has been revised upward, primarily reflecting improved revenue growth forecasts and a slight increase in net profit margin, resulting in a new fair value estimate of A$309.91. What's in the News FDA approved Cochlear’s Nucleus Nexa System, the first smart cochlear implant system with upgradeable firmware, allowing recipients to access future innovations through both the implant and sound processor.Analyseartikel • Jul 16
Cochlear Limited's (ASX:COH) Shares May Have Run Too Fast Too Soon
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 18x, you may consider...
Neues Narrativ • Feb 23
New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects
Focus on adult and senior markets in developed countries could drive revenue and net margin growth through increased sales volume.Aktionärsrenditen
| COH | AU Medical Equipment | AU Markt | |
|---|---|---|---|
| 7D | -2.7% | -2.9% | -0.4% |
| 1Y | -59.9% | -44.0% | 2.0% |
Rendite im Vergleich zur Industrie: COH unter dem Niveau der Branche Australian Medical Equipment , die im vergangenen Jahr eine Rendite von -44% erzielte.
Rendite vs. Markt: COH hinter dem Markt Australian zurück, der im vergangenen Jahr eine Rendite von 2 erzielte.
Preisvolatilität
| COH volatility | |
|---|---|
| COH Average Weekly Movement | 12.6% |
| Medical Equipment Industry Average Movement | 9.7% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.9% |
Stabiler Aktienkurs: COH hatte in den letzten 3 Monaten im Vergleich zum Australian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: COHDie Wöchentliche Volatilität hat sich im vergangenen Jahr von 7% auf 13% erhöht, liegt aber immer noch unter 75% der Aktien von Australian.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1981 | 5,500 | Dig Howitt | www.cochlear.com |
Cochlear Limited bietet weltweit implantierbare Hörlösungen für Kinder und Erwachsene an. Das Unternehmen bietet Cochlear-Implantat-Systeme, Soundprozessor-Upgrades, Knochenleitungssysteme und andere Produkte an. Außerdem bietet es Cochlear-Nucleus-Systeme an, darunter Nucleus-Soundprozessoren, intelligente bimodale Hörlösungen und Nucleus-Implantate; Cochlear-Baha-Systeme, bestehend aus dem Baha 6 max-Soundprozessor und dem Baha-Implantat, sowie Zubehör wie drahtlose Geräte und wasserdichtes Nucleus-Zubehör.
Cochlear Limited's Grundlagenzusammenfassung
| COH grundlegende Statistiken | |
|---|---|
| Marktanteil | AU$7.95b |
| Gewinn(TTM) | AU$345.30m |
| Umsatz(TTM) | AU$2.34b |
23.0x
Kurs-Gewinn-Verhältnis 3.4x
Kurs-Umsatz-VerhältnisIst COH zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| COH Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | AU$2.34b |
| Kosten der Einnahmen | AU$636.90m |
| Bruttogewinn | AU$1.70b |
| Sonstige Ausgaben | AU$1.36b |
| Gewinn | AU$345.30m |
Zuletzt gemeldete Gewinne
Dec 31, 2025
Datum des nächsten Gewinnberichts
Aug 18, 2026
| Gewinn per Aktie (EPS) | 5.28 |
| Bruttomarge | 72.76% |
| Nettogewinnspanne | 14.77% |
| Schulden/Eigenkapital-Verhältnis | 0.7% |
Wie hat sich COH auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
3.5%
Aktuelle Dividendenrendite81%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/12 03:53 |
| Aktienkurs zum Tagesende | 2026/07/10 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/06/30 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Cochlear Limited wird von 26 Analysten beobachtet. 16 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Stuart Roberts | Bell Potter |
| Elisabeth Decou Clive | Bernstein |